Saving Sight Through Novel BioTech Innovations for Inherited Retinal Disease

通过针对遗传性视网膜疾病的新型生物技术创新来拯救视力

• 批准号: nhmrc : 1195713
• 金额: $ 153.45万
• 依托单位国家: 澳大利亚
• 项目类别: Investigator Grants
• 财政年份: 2022
• 资助国家: 澳大利亚
• 起止时间: 2022-01-01 至 2026-12-31
• 项目状态: 未结题
• 来源: https://researchdata.edu.au/saving-sight-through-retinal-disease/1779030
• 关键词: Saving; Sight; Through; Novel; BioTech

Inherited retinal diseases (IRDs) are the leading cause of blindness in working-aged adults. My work focuses on learning more about IRDs, including the correlation between genes and the degenerative changes in the eye. I am developing new outcome measures to predict who might lose vision faster, and to use in clinical trials. I will then use this knowledge in two clinical trials for new IRD treatments - a gene therapy and an electronic device that is implanted into the eye.

遗传性视网膜疾病(IRD)是劳动年龄成年人失明的主要原因。我的工作重点是了解更多关于红斑狼疮的知识，包括基因和眼睛退行性变化之间的相关性。我正在开发新的结果指标，以预测谁可能更快失去视力，并用于临床试验。然后，我将把这一知识用于IRD新疗法的两项临床试验--一种是基因疗法，另一种是植入眼睛的电子设备。